Review of treatment 98 cancer larynx patients

This study included retrospective analysis for 169 patients of laryngeal carcinoma presented to Kasr EI- Eini Center of Radiation oncology and nuclear Medicine at the period 1985-1989 inclusive. Cancer larynx represented 16.25% of all head and neck tumours and 2.04% of all malignancy at the same period. The aim of this work is to study the response to different treatment modalities and to study recurrence rate, disease free interval and survival period for the patients. Only 98 patients attended for regular follow-up for a period of 18 month. 45 patients received radiation therapy only, 38 patients were treated by surgery plus radiation therapy, 9 patients underwent total laryngectomy, 4 patients were treated by radiation therapy plus chemotherapy and 2 patients were treated by radiation therapy, surgery and chemotherapy. Of this group of patients [40.8%] had no evidence of disease recurrence through that period. Recurrence was observed more in cases treated by radiotherapy only [15%] than those treated by surgery and radiotherapy [7%]. Radiotherapy in combination with surgery or alone in dose higher than 50 Gy had better results specially in treatment of locally advanced lesions [T3 - T4] In conclusion, combined treatment modalities in cancer larynx have direct effect on response to treatment, disease free interval and total survival duration. Tumour size, lymph node status have inverse effect on treatment response, disease free interval and total survival also. Regular follow-up and endoscopic examination is advised for proper assessment and early detection of local recurrence

Chemotherapy in advanced and metastatic cancer breast

A retrospective analysis of 120 patients with advanced breast cancer treated with chemotherapy showed that the overall response rate was 34.16%. The response rate was higher for stage III than for stage IV patients, but with lower complete response rate, shorter duration of remission and shorter survival time. Second-line chemotherapy yielded similar results to first line. All regimens yielded comparable results either as a first line or a second line and irrespective of the number of drugs. The subjective response rate exceeded the objective response rate. The response to chemotherapy was influenced by the site of disease and the number of sites involved, the disease free interval and previous response to endocrine therapy. However, age, menstrual status and previous endocrine treatment had little or no effect on response to chemotherapy. Survival of responders exceeded that of non-responders